Alatrofloxacin

Alatrofloxacin

250px
Systematic (IUPAC) name
7-[(1R,5S)-6-{[(2S)-1-{[(2S)- 2-aminopropanoyl]amino}-1-oxopropan-2-yl]amino}- 3-azabicyclo[3.1.0]hexan-3-yl]-1-(2,4-difluorophenyl)- 6-fluoro-4-oxo-1,8-naphthyridine-3-carboxylic acid
Clinical data
Pregnancy category	US: C (Risk not ruled out)
Routes of administration	Intravenous
Legal status
Legal status	Withdrawn
Pharmacokinetic data
Bioavailability	N/A
Protein binding	76% (trovafloxacin)
Metabolism	Quickly hydrolyzed to trovafloxacin
Biological half-life	9 to 12 hours (trovafloxacin)
Excretion	Fecal and renal (trovafloxacin)
Identifiers
CAS Number	157182-32-6 157605-25-9 (mesylate)
ATC code	none
PubChem	CID 5489474
ChemSpider	2343243
Chemical data
Formula	C26H25F3N6O5
Molar mass	558.509 g/mol[[]]

Alatrofloxacin (Trovan IV) is a fluoroquinolone antibiotic developed by Pfizer, delivered as a mesylate salt. It is the parental prodrug of trovafloxacin (Trovan) meant for intravenous administration. Trovafloxacin is a broad-spectrum antibiotic introduced in 1998 which encountered criticism for its Nigerian trials and adverse clinical reactions.

Trovafloxacin and alatrofloxacin were both withdrawn from the U.S. market in 2001.

See also

• Fluoroquinolone toxicity
• Fluoroquinolone

References

it:Alatrofloxacina